A phase 2, open label study of AT-101 in combination with rituximab in patients with relapse[d] or refractory chronic lymphocytic leukemia.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2011
At a glance
- Drugs AT 101; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Ascenta Therapeutics
- 23 Jan 2008 Status changed from in progress to completed according to NCT record
- 09 Oct 2007 Status change
- 08 Sep 2006 New trial record.